| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/25/2004 | CA2498131A1 Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans |
| 03/25/2004 | CA2498111A1 Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
| 03/25/2004 | CA2498106A1 Substituted bicyclic thiophene derivatives, compositions containing such compounds and methods of use |
| 03/25/2004 | CA2498045A1 Compounds for modulating the glycolosis enzyme complex and/or transaminase complex |
| 03/25/2004 | CA2498004A1 Compositions and methods for the diagnosis and treatment of tumor |
| 03/25/2004 | CA2498000A1 Use of tumor-associated kinase (task) 110 antagonists for treating pancreatic cancers |
| 03/25/2004 | CA2497879A1 Use of a combination of dppe with other chemotherapeutic agents for the treatment of breast cancer |
| 03/25/2004 | CA2497661A1 Compositions and methods for the diagnosis of immune related diseases using pro71061 |
| 03/25/2004 | CA2497550A1 Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors |
| 03/25/2004 | CA2497330A1 Novel compositions and methods for the treatment of immune-related diseases |
| 03/25/2004 | CA2497226A1 Pharmaceutical compositions and medical treatments comprising notch ligand proteins |
| 03/25/2004 | CA2497214A1 Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines |
| 03/25/2004 | CA2497192A1 Use of pde iv inhibitors to treat angiogenesis |
| 03/25/2004 | CA2497182A1 Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor |
| 03/25/2004 | CA2497132A1 Method of diagnosing ovarian endometriosis |
| 03/25/2004 | CA2497078A1 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole derivatives and the use of the same as antidepressants |
| 03/25/2004 | CA2497067A1 Amino-propanol derivatives |
| 03/25/2004 | CA2497003A1 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |
| 03/25/2004 | CA2496438A1 An agent for renal failure containing an oxaluric acid derivative |
| 03/25/2004 | CA2496315A1 4-(3,5-dicyanophenoxy) pyrazole derivatives for use as reverse transcriptase modulators in the treatment of i.a. hiv |
| 03/25/2004 | CA2483771A1 Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers |
| 03/24/2004 | EP1400810A2 Estrogen receptors and bone disease |
| 03/24/2004 | EP1400579A2 Composition with anti-oxidative properties |
| 03/24/2004 | EP1400529A1 Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor |
| 03/24/2004 | EP1400523A2 Intermediate compounds |
| 03/24/2004 | EP1400522A1 New compounds for treating impotence |
| 03/24/2004 | EP1400521A1 Piperazine compounds |
| 03/24/2004 | EP1400520A1 Crystal of 6- 4-(4-pyridylamino)phenyl]-4, 5-dihydro-3(2h)-pyridazinone hydrochloride trihydrate |
| 03/24/2004 | EP1400519A1 Respiratory syncytial virus replication inhibitors |
| 03/24/2004 | EP1400518A1 Heterocyclic compound derivatives and medicines |
| 03/24/2004 | EP1400513A1 Unsymmetrical cyclic diamine compound |
| 03/24/2004 | EP1400512A1 Crystalline organic acid salt of amlodipine |
| 03/24/2004 | EP1400510A1 Cyclic diamine compounds having fused-ring groups |
| 03/24/2004 | EP1400249A1 Pharmaceutical preparation of diclofenac sodium |
| 03/24/2004 | EP1400245A1 Boronic acid salts useful in parenteral formulations for selective thrombin inhibition |
| 03/24/2004 | EP1400244A1 New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| 03/24/2004 | EP1400243A1 Calcium-activated K channel activator |
| 03/24/2004 | EP1400242A1 Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor |
| 03/24/2004 | EP1400241A1 Fused cyclic compounds and medicinal use thereof |
| 03/24/2004 | EP1400239A1 Medicinal aerosol formulations of formoterol |
| 03/24/2004 | EP1399739A2 Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
| 03/24/2004 | EP1399738A2 Glaucoma treatments with reduced hyperpigmentation |
| 03/24/2004 | EP1399558A2 Vanilloid receptor-related nucleic acids and polypeptides |
| 03/24/2004 | EP1399548A2 Conjugate of a transport protein and a protein for modulation of notch signalling |
| 03/24/2004 | EP1399542A2 Methods for modulating gap junctions |
| 03/24/2004 | EP1399499A1 Agent for the prevention and treatment of sexually transmitted diseases-i |
| 03/24/2004 | EP1399478A2 Cancer-testis antigens |
| 03/24/2004 | EP1399466A2 Compounds and methods for the modulation of cd154 |
| 03/24/2004 | EP1399462A1 Combined approach to treatment of cancer using a c-myc antisense oligomer |
| 03/24/2004 | EP1399458A1 An arylation method for the functionalization of o-allyl erythromycin derivatives |
| 03/24/2004 | EP1399455A2 Novel tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing same |
| 03/24/2004 | EP1399450A1 Benzoxazepine derivatives and their use as ampa receptor stimulators |
| 03/24/2004 | EP1399449A1 Carbohydrate derivatives |
| 03/24/2004 | EP1399448A1 Imidazo 1,5-a] pyrimido 5,4-d] benzazepine derivatives as gaba a receptor modulators |
| 03/24/2004 | EP1399447A1 Imidazotriazinones derivatives and their use against inflammatory processes and/or immune diseases |
| 03/24/2004 | EP1399446A1 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders |
| 03/24/2004 | EP1399445A2 Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists |
| 03/24/2004 | EP1399444A2 Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as anti-bacterial agents |
| 03/24/2004 | EP1399443A1 Nitrogen-containing bicyclic heterocycles for use as antibacterials |
| 03/24/2004 | EP1399442A1 Cak inhibitors and uses thereof |
| 03/24/2004 | EP1399441A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 03/24/2004 | EP1399440A1 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors |
| 03/24/2004 | EP1399439A1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases |
| 03/24/2004 | EP1399438A1 Novel heteroaryl derivatives, their preparation and use |
| 03/24/2004 | EP1399436A2 Oxytocin agonists |
| 03/24/2004 | EP1399435A2 Pyridine derivatives useful as cd40:cd154 binding interruptors and use thereof to treat immunological complications |
| 03/24/2004 | EP1399434A1 Novel indole derivatives |
| 03/24/2004 | EP1399433A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 03/24/2004 | EP1399432A1 Spiropiperidine compounds as ligands for orl-1 receptor |
| 03/24/2004 | EP1399431A2 Novel nitriles useful as reversible inhibitors of cysteine proteases |
| 03/24/2004 | EP1399430A1 Oxazol/ thiazol-derivatives activators of the hppar-alpha receptor |
| 03/24/2004 | EP1399428A1 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators |
| 03/24/2004 | EP1399426A2 Compounds, compositions and methods for modulating beta-amyloid production |
| 03/24/2004 | EP1399423A2 Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds |
| 03/24/2004 | EP1399422A2 Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl] -1-hydroxybutyl] -a,a-dimethylbenzene acetic acid and its hydrochloride |
| 03/24/2004 | EP1399420A2 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 03/24/2004 | EP1399419A1 New compounds useful in reflux disease |
| 03/24/2004 | EP1399416A2 Peptide deformylase inhibitors |
| 03/24/2004 | EP1399414A2 Substituted tetracycline compounds for the treatment of malaria |
| 03/24/2004 | EP1399411A1 Aloe-emodin derivatives and their use in the treatment of neoplastic pathologies |
| 03/24/2004 | EP1399406A2 Novel estrogen receptor ligands and methods i |
| 03/24/2004 | EP1399221A1 Compositions comprising oestrone-3-o-sulphamate and trail (tnf-related apoptosis inducing ligand) |
| 03/24/2004 | EP1399215A2 Tissue-specific endothelial membrane proteins |
| 03/24/2004 | EP1399206A2 Hydrophobic dopamine agonists administered to the dermis |
| 03/24/2004 | EP1399205A2 Enhanced systemic absorption of intradermally delivered substances |
| 03/24/2004 | EP1399190A1 Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers |
| 03/24/2004 | EP1399188A2 Perylenequinones for use as photosensitizers and sonosensitizers |
| 03/24/2004 | EP1399176A1 Substantially pure glycopeptide antibiotics ac-98-1; ac-98-2; ac-98-3; ac-98-4 and ac-98-5 |
| 03/24/2004 | EP1399175A2 Therapeutic use of rank antagonists |
| 03/24/2004 | EP1399171A1 Medicinal herbal compounds for the prevention and treatment of diabetes |
| 03/24/2004 | EP1399168A1 Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours |
| 03/24/2004 | EP1399167A1 Arylazo-substituted imidazole for the treatment of stress urinary incontinence |
| 03/24/2004 | EP1399166A1 A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID OR 3- 4- 2-(4-TERT- BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL -(s)-2-ETHOXY PROPANOIC ACID AND A SULONYLUREA |
| 03/24/2004 | EP1399165A2 Stabilized dispersion of phytosterol in oil |
| 03/24/2004 | EP1399164A1 Antimycotic agent |
| 03/24/2004 | EP1399163A2 Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection |
| 03/24/2004 | EP1399162A2 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels |
| 03/24/2004 | EP1399161A2 Sustained-release analgesic compounds |
| 03/24/2004 | EP1399160A2 Nr2b receptor antagonists for the treatment or prevention of migraines |
| 03/24/2004 | EP1399159A1 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof |